Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

With the stock's last traded price at Rs 3,081, GlaxoSmithKline Pharmaceuticals has experienced a notable decline, positioning it among the top losers on the Nifty Midcap 150 index.

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Why GSK (GSK) is a Top Value Stock for the Long-Term ... (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance.

GSK is scheduled to report results for the first quarter on Wednesday. Here is what to know. SALES FORECAST: The British pharmaceutical giant is expected to report sales for the period of 7.42 ...